Dermatofibroma (BFH), atypical fibroxanthoma (AFX) and dermal pleomorphic sarcoma (DPS) are skin-based soft-tissue neoplasms of uncertain lineage. They are classified as "fibrohistiocytic" neoplasms, even if the World Health Organization stated that this term connotes a polymorphic group of lesions that histologically resemble fibroblasts and histiocytes. It is well-known that this group of lesions shows a "fibro-histiocytic-dendritic" and/or a "myofibroblastic" phenotype, even within the same lesion. We studied the expression of cathepsin-k in 34 cases (25 BFH, 5 AFX, 4 DPS) with a broad panel of antibodies. 20 cases (5 dermatofibrosarcoma protuberans, 5 melanomas, 5 basal cell carcinomas, 5 squamous cell carcinomas) were chosen as controls. Although our results need to be validated, they support a myofibroblastic and/or partial myofibroblastic ("proto-myofibroblastic") phenotype and the lineage-plasticity of these neoplasms, highlighting the potential role of cathepsin-k in myofibroblastic trans-differentiation. Cathepsin-k proved to be an additional immunoistochemical marker potentially useful in the diagnostic algorithm.

中文翻译：

---

组织蛋白酶-k是否可以驱动在皮肤纤维瘤，非典型纤维黄瘤和多形性皮肤肉瘤中观察到的肌成纤维细胞分化？

皮肤纤维瘤（BFH），非典型纤维黄瘤（AFX）和皮肤多形性肉瘤（DPS）是谱系不确定的基于皮肤的软组织肿瘤。即使世界卫生组织指出该术语表示组织学上类似于成纤维细胞和组织细胞的多态性病变组，它们仍被分类为“纤维组织细胞性”肿瘤。众所周知，即使在同一病变内，这组病变也显示出“纤维组织细胞-树突状”和/或“肌成纤维细胞”表型。我们研究了34例具有广泛抗体的组织蛋白酶-k的表达（25 BFH，5 AFX，4 DPS）。选择20例（5例隆突性皮肤纤维肉瘤，5例黑色素瘤，5例基底细胞癌，5例鳞状细胞癌）作为对照。尽管我们的结果需要验证，它们支持肌成纤维细胞和/或部分肌成纤维细胞（“原肌成纤维细胞”）表型以及这些肿瘤的谱系可塑性，突出了组织蛋白酶-k在肌成纤维细胞转分化中的潜在作用。组织蛋白酶-k被证明是可能在诊断算法中有用的另一种免疫组织化学标记。